Assessment of Molecular Remission by ASO-RQ-PCR Technique After Induction Treatment With Bortezomib-Dexamethasone (Vel/Dex) Followed by HDT With ASCT
Phase of Trial: Phase II/III
Latest Information Update: 27 Oct 2015
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Melphalan
- Indications Multiple myeloma
- Focus Therapeutic Use
- 01 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 10 May 2013 Planned end date changed from 1 Nov 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 17 Feb 2012 Planned end date changed from 1 Jul 2012 to 1 Nov 2013 as reported by ClinicalTrials.gov.